This story has been updated to include comments made by NantHealth management during a conference call.

CHICAGO (GenomeWeb) — NantHealth’s revenues for the third quarter increased by 5 percent year over year, the company said after the markets closed on Thursday.

For the three months ended Sept. 30, the Culver City, California-based firm posted revenues of  $21.8 million, up from $20.7 million in the same period a year earlier. It missed the consensus Wall Street estimate of $29.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.